The 5th International Summit on Cell and Gene Therapy in China was held in Nanjing from May 22nd to 24th, 2024. As a global leader in CAR-M targeted therapy for solid tumors, RocRock Biotech has been honored with the CGCS Awards Rising Star Award in Cell Therapy R&D for its innovative achievements in the field of biomedicine.

Since its establishment, RocRock Biotech has consistently focused on researching macrophage drug therapies for cancer. With its unique set of four core platforms as the technological foundation, the company is dedicated to developing macrophage drugs to address significant challenges in the field of solid tumor treatment. In 2023, RocRock Biotech, in collaboration with the Affiliated Hospital of Xuzhou Medical University, initiated an Investigator Initiated Trial (IIT) for the RR-M01 pipeline and successfully completed the dosing assessment for two subjects. The indications for pipeline RR-M01 have been further expanded to include all solid tumors that are HER2-positive or have low expression, and in early March 2024, it obtained ethical approval from the Affiliated Hospital of Xuzhou Medical University, with the first patient already enrolled. To date, the company has successfully advanced two cell drugs to the IIT stage and completed tens of millions of yuan in Pre-A round financing in February 2024, while also initiating the IND filing for the third-generation CAR-M. These impressive achievements and progress have not only gained official recognition from authoritative institutions but also received support from the public jury. RocRock Biotech is proud to receive the CGCS Awards Rising Star Award, which stands as the best testament to the company's accomplishments in the field of biomedicine.

Alongside the award, Dr. Yin Xiushan, the founder of RocRock Biotech, was also invited to participate in the pre-CGCS 2024 high-level closed-door meeting held concurrently. Senior experts from various fields of biomedicine gathered to discuss the latest advancements, challenges, collaboration opportunities, and future development trends in the biomedicine industry. During the meeting, Dr. Yin Xiushan generously shared the latest research findings on RocRock's CAR-M therapy for solid tumors and explored the possibilities of combining CAR-M with other cell therapies with other corporate leaders. He also offered constructive suggestions on how to promote industry innovation and strengthen collaboration between industry and academia. This closed-door meeting not only demonstrated RocRock Biotech's influence within the industry but also provided valuable opportunities for exchange and cooperation for RocRock's future development.

As the highest-profile annual conference in the fields of cell and gene therapy, nucleic acid drugs, and organoids, the event gathers over 200 globally renowned speakers and more than 5,000 industry professionals participating offline. It covers the latest and most comprehensive topics, including regulatory interpretations of cell and gene therapies, clinical and R&D production of cell therapies, development of novel cell treatments, AAV gene therapy, development of stem cell drugs, organoids and 3D cell culture, oncolytic virus development, mRNA therapy, small nucleic acid drug development, and tumor neoantigen vaccines.